Harnessing the Power of Ultra-Sensitive ctDNA Detection For Molecular Response & Endpoint Across All Phases of Clinical Development
- Personalis is the pioneer of ultra-sensitive tumor informed whole genome based ctDNA testing, and NeXT Personal remains the leader in the field with robust clinical validation/evidence generation
- Learn how NeXT Personal can play a pivotal role in ctDNA biomarker-driven clinical development, and how Personalis can be a partner for endpoint analyses thereby improving decision making to advance patient care